Brief: Cereno Scientific Receives FDA Clearance To Initiate Global Phase IIb Trial Of CS1 In Pulmonary Arterial Hypertension
08/12/2025 21:26
Dec 8 (Reuters) - Cereno Scientific AB CRNOSb.ST: CERENO SCIENTIFIC RECEIVES FDA CLEARANCE TO INITIATE GLOBAL PHASE IIB TRIAL OF CS1 IN PULMONARY ARTERIAL HYPERTENSION (PAH) Source text: ID:nWkr3Z81PS Further company coverage: [CRNOSb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global